Dingke Medical Completes Series E Financing of Several Hundred Million RMB to Advance Its Comprehensive Portfolio of Interventional Balloons Across Vascular Fields

Jun 21, 2024 10:26 CST Updated 10:26

DK Medtech

Vascular Interventional Balloon Product Developer

Commercialization layout proceeds smoothly.

This article is an original piece by IPO Early Bird.

Author｜Stone Jin

WeChat Official Account | ipozaozhidao

According to IPO Early Bird News, DK Medical Technology Co., Ltd. (hereinafter referred to as "DK Medtech") has recently completed a Series E round of financing worth hundreds of millions of yuan. This round of financing was jointly led by Legend Capital and Qiming Venture Partners, with the angel round investment institution of DK Medtech also participating in the investment.

The funds from this round of financing will be used to strengthen the manufacturing center and commercialization construction, further enhance DK Medtech's advantages in technology and product innovation, and simultaneously plan for overseas market investment and expansion.

Founded in 2015TheDK MedtechAs aInnovative Enterprise in Full Range of Interventional Balloons，Developed more than ten types of balloons, including standard balloons, high-pressure balloons, scoring balloons, and drug-coated scoring balloons. The product line covers the needs of almost all vascular intervention fields, including cardiovascular intervention, peripheral intervention, and neurointervention., nowObtained 13 Class III medical device registration certificates and completed pre-market RCT clinical studies for 5 special types of balloon catheters.

According to the official product information released by DK Medtech, the current patented technology for directional scoring is used in coronary scoring balloons, peripheral scoring balloons, and scoring drug-coated balloons. Moreover, based on the published pre-market RCT studies of these products, their clinical performance shows significantly greater clinical benefits compared to the imported control groups.

It is worth mentioning that,DK Medtech's Coronary Scoring Balloon Dilation Catheter (China Medical Device Registration No. 20223031162), Scoring Balloon Dilation Catheter (China Medical Device Registration No. 20223031527), and Peripheral Scoring Drug-Coated Balloon Dilation Catheter (China Medical Device Registration No. 20233030980) are all the first products in their respective categories to obtain certification.

Leveraging the advantages of product performance, DK Medtech's commercialization layout is proceeding smoothly — In the field of hemodialysis access, DK Medtech’s balloon has entered the first tier. The company offers a global solution in this field and has signed a general agency cooperation agreement with US-based Pulse Medical for the LifeSpan artificial blood vessel. In the peripheral intervention field, DK Medtech released, for the first time, the world's largest RCT study on special balloons at the Leipzig Interventional Course (LINC2024) in Germany this May. The study achieved excellent results and received significant attention from international experts. In the coronary balloon field, DK Medtech has reached multiple strategic cooperations with Medtronic and Asahi Intecc. Through the mature marketing systems of these international giants, they jointly promote domestically produced innovative products.

DK Medtech founder Weng Yulin stated: "The original intention of DK's entrepreneurship is to do things differently, with precision.""Regardless of how policies and markets change, persisting in creating products that truly address clinical pain points is what gives a product vitality and social value."

Zhou Quan, Managing Director of Legend Capital, said: "DK Medtech has addressed and evaluated actual clinical pain points, and through independent research and innovation, it has effectively met clinical needs and created products that rival world-class standards."DK Medtech's technical R&D capabilities represent high-end medical device consumables produced in China. Based on product characteristics, the company has adopted a dual-track commercialization strategy to rapidly implement commercialization."We highly recognize the Dikang Medical team and their efficient execution capabilities. It is a great honor to join hands with Dikang Medical and develop together."

Zhang Ao, Executive Director of Qiming Venture Partners, said: "During our investment process, DK Medtech has achieved many milestones. Both in terms of product line design planning and commercialization layout, it demonstrates strategic thinking.We are optimistic about the future development of DK Medtech and look forward to the company becoming a leader in the interventional balloon field in the near future, evolving into a full technology platform specializing in precision balloons."

This article was originally written by the WeChat Official Account IPO Early Know (ID: ipozaozhidao). If you need to reprint, please contact C-Shu ↓↓↓

Guoquan｜October Rice Field｜UBTECH｜Lalamove
JAKA Robotics｜Ark Bio｜Aikang Medical｜NorthX
ZhiXing Technology｜OneRay Medical｜Ruipu Lanjun｜Kelun Botai